COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

SuperB Trial: SUrgical Versus PERcutaneous Bypass (SuperB)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01220245
Recruitment Status : Active, not recruiting
First Posted : October 13, 2010
Last Update Posted : October 14, 2019
Information provided by (Responsible Party):
Michel Reijnen, Rijnstate Hospital

Brief Summary:
In this multicentre Randomized Clinical Trial, the heparin-bonded endoluminal bypass will be compared to the surgical venous femoro-popliteal bypass, based on the non-inferiority principle for the patency. Besides equal patency, an improved quality of life is expected. Recruitment will take the first two years and patients will be followed during five years. Patients with an indication for surgical bypass, classified category 3-6 with a >50% stenosis or occlusion of the SFA over >/=10 cm in length will be included. At least one crural artery should be patent without significant lesions.

Condition or disease Intervention/treatment Phase
Cardiovascular Diseases Procedure: Heparin-bonded ePTFE endoluminal fem-pop bypass Procedure: Surgical femoro-popliteal bypass. Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 126 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Heparin-bonded Endoluminal Versus Surgical Femoropopliteal Bypass; a Multicentre Randomized Controlled Trial
Study Start Date : October 2010
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : July 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Thinners

Arm Intervention/treatment
Experimental: Heparin-bonded endoluminal fempop bypass
Heparin-bonded ePTFE endoluminal femoro-popliteal bypass versus surgical femoro-popliteal bypass
Procedure: Heparin-bonded ePTFE endoluminal fem-pop bypass
Heparin-bonded ePTFE endoluminal femoropopliteal bypass versus surgical femoropopliteal bypass

Active Comparator: Surgical femoro-popliteal bypass
Surgical femoro-popliteal bypass.
Procedure: Surgical femoro-popliteal bypass.
Surgical femoro-popliteal bypass.

Primary Outcome Measures :
  1. Primary (and -assisted) patency [ Time Frame: 5 years ]
  2. Quality of life [ Time Frame: 5 years ]

Secondary Outcome Measures :
  1. Secondary patency [ Time Frame: 5 years ]
  2. Complications [ Time Frame: 5 years ]
  3. Clinical improvement [ Time Frame: 5 years ]
  4. Re-intervention [ Time Frame: 5 years ]
  5. Target lesion revascularisation [ Time Frame: 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age over 18 years
  • Informed consent
  • Novo stenosis, restenosis >50% or occlusion of the native SFA, all > 10cm in length
  • Patent popliteal artery at the upper margin of the patella to the trifurcation
  • Diameter native SFA and popliteal artery are 5.0-7.5 mm
  • Indication for surgical bypass
  • Distal run-off at least one crural artery without significant stenosis
  • Ankle-brachial index (ABI) at rest < 0.8 in the study limb prior to procedure

Exclusion Criteria:

  • Patient unsuitable for administration of contrast agent
  • Pregnancy
  • Dementia or altered mental status that would prohibit giving conscious informed consent
  • Need for adjunctive major surgical or vascular procedures within one month
  • Untreated flow-limiting aortoiliac occlusive disease
  • Perioperative unsuccessful ipsilateral percutaneous vascular procedure to treat inflow disease just prior to enrollment
  • Femoral or popliteal aneurysm of target vessel
  • Non-arthrotic disease resulting in occlusion (e.g. embolism, Buerger's disease, vasculitis)
  • Severe medical comorbidities (untreated CAD/CHF, severe COPD, metastatic malignancies, dementia etc.) or other medical condition that would preclude compliance with study protocol
  • Major distal amputation (above the transmetatarsal) in the study limb
  • Any previously known coagulation disorder, including hypercoagulability
  • Contraindication to anticoagulation or antiplatelet therapy
  • Known allergies to stent/stent-graft components
  • History of prior life-threatening reaction to contrast agent
  • Patients with known hypersensitivity to heparin, including those patients who have had a previous incidence of heparin-induced thrombocytopenia (HIT) type II
  • Planned surgical procedure or major amputation to occur after enrollment of the patient

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01220245

Layout table for location information
Nij Smellinghe Hospital
Drachten, Friesland, Netherlands
Antonius Hospital
Sneek, Friesland, Netherlands
Rijnstate Hospital
Arnhem, Gelderland, Netherlands
Slingeland Hospital
Doetinchem, Gelderland, Netherlands
Isala klinieken
Zwolle, Overijssel, Netherlands
University Medical Centre Groningen
Groningen, Netherlands
Sponsors and Collaborators
Rijnstate Hospital
Layout table for investigator information
Principal Investigator: MMJP Reijnen, MD, PhD Rijnstate Hospital
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Michel Reijnen, Principal Investigator, Rijnstate Hospital Identifier: NCT01220245    
Other Study ID Numbers: 721-070910
First Posted: October 13, 2010    Key Record Dates
Last Update Posted: October 14, 2019
Last Verified: October 2019
Keywords provided by Michel Reijnen, Rijnstate Hospital:
quality of life
superficial femoral artery
vascular patency
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action